Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On the 11th February the MsC IHTM students visited the House of Parliament and presented their policy briefs in the House of Lords.

MSc IHTM team visiting the Houses of Parliament
Photo of the 2019-2020 MSc IHTM cohort visiting to the Houses of Parliament

The five briefs focused on a variety of themes:

  • providing better universal healthcare by strengthening better primary health care and improving digital health tech
  • develop affordable diagnostic tools and medicines for neglected tropical diseases
  • benefits and risks of multi-sectoral collaboration in the funding of neglected tropical diseases programmes
  • benefits of investing in programmes that improve child health through immunisation & nutrition
  • potential collaboration between UK and Bangladeshi governments to ensure the hepatitis C crisis amongst the Rohingya refugees in Cox’s Bazar is contained and extinguished

The presentations were very well received by our host Lord Tress, Lord Collins of Highbury and Mr Jeremy Lefroy (former chair of the APPG NTDs).

Similar stories

RECOVERY Trial announced as overall winner of Best COVID-19 Response Project Award in the UK

The RECOVERY Trial has won the Project Management Institute’s Special Covid-19 UK Response Project Award. The award specifically recognised RECOVERY’s work to investigate whether the cheap steroid dexamethasone was an effective treatment for patients hospitalised with severe COVID-19.

ISARIC COVID-19 clinical database passes ½ million patient records mark

COVID-19 has exposed our vulnerability to pandemic infections and shown what works, and what does not. It has tested the effectiveness of the Oxford-based global, open-source, collaborative approach set up 10 years ago to prevent illness and deaths from infectious disease outbreaks: ISARIC, the International Severe Acute Respiratory and Emerging Infection Consortium.

RECOVERY Trial named joint winner of HDR UK’s Impact of the Year Award

The RECOVERY trial has been jointly awarded Health Data Research UK’s 2021 Impact of the Year Award. This award is open to projects which had effectively used health data to improve people’s lives, including through clinical practice, policy, software, algorithms, or publications. The award was presented by James O’Shaughnessy at HDR UK’s online Annual Scientific Conference: Data Insights in a Pandemic.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

Sandra Adele (cohort 2020-2021) co-authored this paper on the efficacy of the Oxford Astra-Zeneca vaccine for the 40 million people globally living with HIV. This study aimed to assess the vaccine’s ability to stimulate an immune response on those who have their immunity compromised.

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.